We are partnering with third parties to prepare sustained release formulations and/or deliver therapeutic agents, including small and large molecules, and gene and cell therapies, to treat retinal diseases.
Our drug administration technology enables routine administration to deliver drugs to specific back-of-eye tissues, including the suprachoroidal, sub-retinal, and other small spaces.
Our drug formulations are designed to suit the unique ocular environments into which they are delivered, resulting in better drug movement and therapeutic benefits. They provide effects lasting up to 12 months from a single administration.
If you would like to discuss a potential partnership with Oxular, working with either our device or drug formulation technologies, please contact us on the form below.